|
|
Blood, 1 September 2007, Vol. 110, No. 5, pp. 1603-1606.
Prepublished online as a Blood First Edition Paper on April 26, 2007; DOI 10.1182/blood-2007-01-066258.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Brief Report
Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia
Elena E. Solomou1,
Katayoun Rezvani1,
Stephan Mielke1,
Daniela Malide2,
Keyvan Keyvanfar1,
Valeria Visconte1,
Sachiko Kajigaya1,
A. John Barrett1, and
Neal S. Young1
1 Hematology Branch and
2 Light Microscopy Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Regulatory T cells are believed to control the development and progression of autoimmunity by suppressing autoreactive T cells. Decreased numbers of CD4+CD25+ FOXP3+ T cells (Tregs) are associated with impaired immune homeostasis and development of autoimmune diseases. The transcription factors FOXP3 and NFAT1 have key roles in regulatory T-cell development and function. We show that Tregs are decreased at presentation in almost all patients with aplastic anemia; FOXP3 protein and mRNA levels also are significantly lower in patients with aplastic anemia and NFAT1 protein levels are decreased or absent. Transfection of FOXP3-deficient CD4+CD25+ T cells from patients with a plasmid encoding wild-type NFAT1 resulted in increased FOXP3 expression in these cells. By NFAT1 knockdown in CD4+CD25+ T cells, FOXP3 expression was decreased when NFAT1 expression was decreased. Our findings indicate that decreased NFAT1 could explain low FOXP3 expression and diminished Treg frequency in aplastic anemia. Treg defects are now implicated in autoimmune marrow failure.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
V. Visconte, N. Raghavachari, D. Liu, K. Keyvanfar, M. J. Desierto, J. Chen, and N. S. Young
Phenotypic and functional characterization of a mouse model of targeted Pig-a deletion in hematopoietic cells
Haematologica,
February 1, 2010;
95(2):
214 - 223.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Q. Tran, J. Andersson, D. Hardwick, L. Bebris, G. G. Illei, and E. M. Shevach
Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures
Blood,
May 21, 2009;
113(21):
5125 - 5133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Oh, G. Blevins, C. Griffith, N. Richert, D. Maric, C. R. Lee, H. McFarland, and S. Jacobson
Regulatory T Cells Are Reduced During Anti-CD25 Antibody Treatment of Multiple Sclerosis
Arch Neurol,
April 1, 2009;
66(4):
471 - 479.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Feng, S. Kajigaya, E. E. Solomou, K. Keyvanfar, X. Xu, N. Raghavachari, P. J. Munson, T. M. Herndon, J. Chen, and N. S. Young
Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro
Blood,
April 1, 2008;
111(7):
3675 - 3683.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bacigalupo
Aplastic Anemia: Pathogenesis and Treatment
Hematology,
January 1, 2007;
2007(1):
23 - 28.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|